Objective: Pregnanolone is a 3α-hydroxylated-5β-reduced metabolite of the female sex steroid hormone progesterone. The compound is currently being evaluated for anaesthetic purposes. Previous studies have indicated a differential physiological response across the menstrual cycle and a different response in patients with premenstrual syndrome (PMS). This study was undertaken to determine whether hormonal changes during the menstrual cycle influence pregnanolone pharmacokinetics and to compare PMS diagnosis-related differences in pregnanolone pharmacokinetics.
Methods: Seven patients with premenstrual syndrome and seven female controls were given three increasing doses of pregnanolone in the follicular and luteal phase of the menstrual cycle.
Results: Mean pregnanolone elimination half-life varied between 28.4 min and 31.8 min and clearance between 59.6 ml · min−1 · kg−1 and 64.0 ml · min−1 · kg−1, depending on diagnostic group and cycle phase. No significant differences in pregnanolone pharmacokinetic properties were found between PMS patients and controls in either phase of the menstrual cycle. Furthermore, no differences in pharmacokinetic variables were detected between cycle phases.
Conclusion: Pregnanolone pharmacokinetics do not differ between follicular and luteal phase of the menstrual cycle, nor between PMS patients and control subjects.
This is a preview of subscription content, log in via an institution to check access.
Access this article Subscribe and saveSpringer+ Basic
€34.99 /Month
Price includes VAT (Germany)
Instant access to the full article PDF.
Similar content being viewed by others Explore related subjectsDiscover the latest articles and news from researchers in related subjects, suggested using machine learning. Author information Authors and AffiliationsDepartment of Obstetrics and Gynaecology, University Hospital of Umeå, S-901 85 Umeå, Sweden e-mail: inger.sundstrom@obstgyn.umu.se Tel.: +46-90-785-34 61; Fax: +46-90-785-22-00, , , , , , SE
I. Sundström & T. Bäckström
Department of Clinical Pharmacology, Regional and University Hospital, Trondheim, Norway, , , , , , NO
O. Spigset
Department of Physiology, Umeå University, Umeå, Sweden, , , , , , SE
A. Andersson
Department of Analytical Chemistry, Umeå University, Umeå, Sweden, , , , , , SE
P. Appelblad
Received: 16 September 1998 / Accepted in revised form: 27 November 1998
About this article Cite this articleSundström, I., Spigset, O., Andersson, A. et al. Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics. E J Clin Pharmacol 55, 125–130 (1999). https://doi.org/10.1007/s002280050606
Issue Date: April 1999
DOI: https://doi.org/10.1007/s002280050606
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4